Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeted radionuclide therapy: frontiers in theranostics.

Francesca Gallivanone1, Mauro Valente2, Annarita Savi3

  • 1Institute of Molecular Bioimaging and Physiology, National Research Council (IBFM-CNR), Milan, Italy, francesca.gallivanone@ibfm.cnr.it.

Frontiers in Bioscience (Landmark Edition)
|April 15, 2017
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic accuracy of modern imaging following neoadjuvant therapy for breast cancer: a comparative analysis of ultrasound versus [18F] FDG PET/MRI in breast response assessment.

Frontiers in oncology·2026
Same author

Hyperspectral imaging and healthy aging: an observational study using hand skin as surface for monitoring healthy aging processes.

Biogerontology·2026
Same author

First-in-human <i>ex-vivo</i> validation of carbonic anhydrase IX-PET for high-risk renal cancer (CAT-VHL - PNRR-POC-2023-12377493).

Theranostics·2026
Same author

Advancing Brain Tumor Diagnosis Using Deep Learning: A Systematic and Critical Review on Methodological Approaches to Glioma Segmentation and Classification Through Multiparametric MRI.

Brain sciences·2026
Same author

Hybrid [<sup>18</sup>F]FDG PET/MR Imaging Parameters for the Prediction of Tissue Biomarkers in Invasive Ductal Breast Cancer.

Bioengineering (Basel, Switzerland)·2026
Same author

Personalized dosimetry enhances hepatocellular carcinoma response in Yttrium-90 resin microsphere radioembolization.

European radiology·2026

Targeted radionuclide therapy (TRT) uses nuclear medicine for precise cancer treatment. Combining imaging with therapy, known as theranostics, personalizes treatment and monitors effectiveness.

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Radiochemistry

Background:

  • Targeted radionuclide therapy (TRT) utilizes systemically administered radiopharmaceuticals for precise cellular or molecular targeting in cancer treatment.
  • Advances in radionuclide production, radiolabeling techniques, and molecular target identification have significantly fueled interest in TRT.
  • Recent research emphasizes TRT's potential in theranostic applications, integrating diagnostic imaging with therapeutic interventions.

Purpose of the Study:

  • To review recent literature on targeted radionuclide therapy (TRT).
  • To focus on clinical applications of TRT that employ a theranostic approach.
  • To highlight the synergistic impact of diagnostic imaging and therapeutics in TRT.

Main Methods:

  • Literature review of recent studies on TRT.

Related Experiment Videos

  • Analysis of clinical applications focusing on theranostic approaches.
  • Evaluation of studies combining diagnostic imaging and therapeutic radionuclides.

    • Main Results:

    • TRT shows promise for precise, targeted cancer treatment.
    • Theranostic approaches combining imaging and therapy enable personalized treatment strategies.
    • Accurate dosimetry and therapy monitoring are crucial for optimizing TRT outcomes.

    Conclusions:

    • TRT, particularly with a theranostic approach, offers personalized cancer treatment.
    • The synergy between diagnostic imaging and therapeutic radionuclides is key to optimizing treatment efficacy and patient outcomes.
    • Continued research in TRT and theranostics is vital for advancing oncological care.